Form 144 BioNTech SE Filed by: Tureci Ozlem
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
BioNTech (BNTX) PT Raised to $121 at Leerink Partners
November 13, 2024 7:26 AM ESTLeerink Partners analyst Daina Graybosch raised the price target on BioNTech (NASDAQ: BNTX) to $121.00 (from $102.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: BioNTech (BNTX, OP) seeks to drive top-line growth through excellence in oncology drug development, and tomorrow's Innovation Series (11/14) event is poised to be an important... More
